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Introduction
The myelodysplastic syndromes (MDS) 
are a heterogeneous group of clonal cell 
disorders characterized by ineffective 
hematopoiesis manifested by one or more 
cytopenias.
1
 The incidence is higher in men, 
and is about 3-4 individuals per 100,000 in 
the United States and may exceed 20/ 
100,000 persons after the age of 70 years.
2
 
Risk factors for development of MDS 
include prior chemotherapy, radiation 
therapy, smoking, and exposure to benzene. 
The most common cytogenetic alteration in 
MDS is a deletion of the short arm of 
chromosome 5. We report a patient with an 
isolated trisomy 21, which constitutes about 
1.1-2.2 % of the total cytogenetic alterations 
in MDS.
3,4
 To our knowledge, this is the 
first reported case of autoimmune hemolytic 
anemia (AIHA) and MDS with isolated 
trisomy 21. 
 
Case Report 
A 62-year-old Caucasian male was 
initially admitted for generalized weakness 
and fatigue. The symptoms started three 
months prior to presentation at the referring 
hospital. The patient reported anorexia, 
weight loss, and exercise intolerance. He 
denied any bleeding symptoms to suggest 
infection. On admission to our hospital, his 
vital signs were within normal limits. His 
physical exam showed pallor, but otherwise 
was unremarkable. 
Initial labs are summarized in Table 1. 
His peripheral smear showed 65% 
neutrophils, 9% bands, 9% blasts, 2% 
metamyelocytes, and 1% myelocytes. He 
underwent a bone marrow biopsy, which 
was consistent with myelodysplastic 
syndrome (RAEB-1). His cytogenetics 
showed trisomy 21 as the sole abnormality.  
Testing for vitamin B12 and folic acid were 
unremarkable. The patient was diagnosed 
with AIHA and treatment was started with 
prednisone at 1 mg/kg.   
The patient’s hemoglobin improved with 
prednisone. The prednisone was tapered 
over two months and his Coombs testing 
became negative shortly after the course. 
The patient’s platelet count continued to 
deteriorate and treatment was initiated with 
the hypomethylating agent, decitabine. The 
patient tolerated this treatment well and had 
improvement in his cytopenia. His course 
was complicated by gastrointestinal bleeding 
and a pneumonic infection. The patient died 
from complications of an empyema. 
 
Discussion 
This case illustrates a commonly 
overlooked association between two 
different hematologic diseases, myelo-
dysplastic syndrome and autoimmune 
hemolytic anemia. Our patient had evidence 
of intravascular hemolysis, manifested by 
his reticulocytosis,  high LDH and  bilirubin,  
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Table 1.  Initial labs obtained on admission. 
 
 
 
 
 
 
 
 
 
and low haptoglobin. There was evidence of 
autoimmunity with the Coombs test positive 
for pan agglutinating IgG. This improved 
with standard first line treatment. The bone 
marrow biopsy result was consistent with 
myelodysplastic syndrome, refractory 
anemia with excess blasts (RAEB-1 with 7% 
blasts in the bone marrow).  
Autoimmune hemolytic anemia is due to 
the immunologic destruction of red blood 
cells mediated by autoantibodies directed 
against red blood cells antigens.
5
 The 
antibodies can be of “warm” or “cold” 
subtype. The majority of warm agglutinins 
are IgG subclass antibodies. They react to 
antigens at body temperature in contrast to 
cold agglutinins which are mostly IgM 
subclass, and react to RBC antigens at a 
temperature lower than the body’s core 
temperature. The diagnosis usually is made 
with the finding of an elevated reticulocyte 
count, increased lactate dehydrogenase, and 
indirect bilirubin in the setting of a positive 
direct Coombs test (direct antiglobulin test). 
There is increasing evidence that 
autoimmunity plays an important role in 
myelodysplastic syndromes. Autoimmune 
manifestations (AIM) are more common 
than thought in the setting of MDS. Their 
frequency ranges from 10-18.5% of patients 
with MDS.
6,7
 These manifestations can be 
classified into five classes:
4
 
1) Acute systemic vasculitis or auto-
immune disorder. 
2) Chronic or isolated autoimmune 
phenomena. 
3) Classical connective tissue disorders. 
4) Immune-mediated hematological 
abnormalities. 
5) Asymptomatic serological immuno-
logic abnormalities. 
The association of AIM and MDS was 
first described in 1982 as AIHA one year 
after the diagnosis of MDS.
6
 Subsequently, 
multiple cases and studies have been 
published emphasizing the relationship 
between autoimmunity and MDS.  
In a study by Sokol et al.,
8
 15 of 46 
patients with MDS had clinically important 
autoimmune hemolysis. Pendry et al.
9
 
reported a case of MDS presenting as AIHA. 
The first pediatric case was reported by 
Ören et al.
10
 The improvement of both 
disorders was noticed with mycophenolate 
mofetil.
11
 João et al.
12
 and Terpos et al.
13
 
described two cases of MDS, AIHA, and 
non-Hodgkin’s lymphoma. Giagounidis et 
al.
14
 reported a case of AIHA and a case of 
autoimmune arthritis in association with 
MDS with 5q deletion. Pilorge et al.
15
 
reported three cases of AIM and MDS with 
improvement with 5-azacitidine.  
The pathogenesis of the association of 
these two disorders is still unclear. Current 
hypotheses relate development of auto-
immune hemolytic anemia to dysregulated 
immunity. In a study by Barcellini et al.,
16
 
53.8% of patients showed autoimmune 
Lab Hb 
(g/dL) 
WBC 
(×10
9
/L) 
Platelets 
(×10
9
/L) 
MCV 
(mm
3
) 
Reticulocyte 
count 
Values 10.5 24.2 37 99 9.3% 
Lab LDH 
(IU/L) 
Haptoglobin 
(mg/dL) 
Bilirubin 
(mg/dL) 
Coombs test 
Values 568 3 2.8 Positive 
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phenomena to erythroblasts in the bone 
marrow, but none in the peripheral 
blood.
14,16
 
AIHA in MDS may be underdiagnosed 
for several reasons including the assumption 
that anemia is due to MDS.
14
 Besides, 
Coombs-negative hemolytic anemia can be 
masked by reticulocytopenia caused by 
MDS.  
It is unclear if autoimmune manifest- 
ations carry any prognostic implications to 
the diagnosis of MDS. In a study by Enright 
et al.,
17
 patients with the combination of the 
two disorders were younger, more often had 
MDS related to prior chemotherapy, and had 
additional cytogenetic abnormalities. The 
onset of AIM was associated with clinical 
deterioration, as the median survival after 
AIM diagnosis was only nine months 
compared to 25 months after MDS 
diagnosis. In addition, the initial response to 
steroids carried a better prognosis. 
 
Conclusion 
Autoimmune hemolytic anemia is a rare, 
but commonly overlooked cause of anemia 
in patients with myelodysplastic syndrome. 
Further reports may delineate the association 
of autoimmune manifestations and MDS 
better and its potential prognostic and 
therapeutic implications. A link may be 
found between chromosomal abnormalities 
and their concomitant incidence. 
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